Galectin Therapeutics reports Q4 EPS (15c) vs (19c) last year

Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics (GALT), stated “This quarter, we remained laser-focused on advancing additional analyses for belapectin. I was extremely encouraged by the feedback we received last week at the European Association for the Study of the Liver, specifically that we successfully demonstrated a clinically significant response in a key biomarker that is used to support outcomes in MASH trials at every stage of disease progression. In December 2024, as part of the topline results from the NAVIGATE trial, we reported that the 2 mg/kg dose of belapectin led to a significantly lower incidence of new varices compared to placebo in the per protocol population-validating the findings from our earlier Phase 2 study where 2 mg/kg dose showed significant reduction in portal pressure and new varices in cohort of patients without varices at baseline.